Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment
FEMS Microbiology Reviews · 2024
DOI: 10.1093/femsre/fuae011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift FEMS Microbiology Reviews, 2024. Verfasst von Eva Habjan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Microbiology and Infection Control, Amsterdam UMC, Location VU Medical Center,De Boelelaan 1108, 1081 HZ Amsterdam, The Netherl…. Hauptthemen laut MEDLINE: Zebrafish, Drug Discovery, Drug Evaluation, Preclinical, Embryo, Nonmammalian. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 195 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NWO.
Abstract (Originalsprache)
The rise of multidrug-resistant bacteria underlines the need for innovative treatments, yet the introduction of new drugs has stagnated despite numerous antimicrobial discoveries. A major hurdle is a poor correlation between promising in vitro data and in vivo efficacy in animal models, which is essential for clinical development. Early in vivo testing is hindered by the expense and complexity of existing animal models. Therefore, there is a pressing need for cost-effective, rapid preclinical models with high translational value. To overcome these challenges, zebrafish embryos have emerged as an attractive model for infectious disease studies, offering advantages such as ethical alignment, rapid development, ease of maintenance, and genetic manipulability. The zebrafish embryo infection model, involving microinjection or immersion of pathogens and potential antibiotic hit compounds, provides a promising solution for early-stage drug screening. It offers a cost-effective and rapid means of assessing the efficacy, toxicity and mechanism of action of compounds in a whole-organism context. This review discusses the experimental design of this model, but also its benefits and challenges. Additionally, it highlights recently identified compounds in the zebrafish embryo infection model and discusses the relevance of the model in predicting the compound’s clinical potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Microbiology and Infection Control, Amsterdam UMC, Location VU Medical Center,De Boelelaan 1108, 1081 HZ Amsterdam, The Netherlands.
- Section Molecular Microbiology of A-LIFE, Vrije Universiteit, De Boelelaan 1085, 1081 HV Amsterdam, The Netherlands.
ORCID-Profile: Eva Habjan, Gina K Schouten, Alexander Speer, Peter van Ulsen, Wilbert Bitter
Förderung
- NWO
Zitieren
APA
Habjan, E., Schouten, G. K., Speer, A., van Ulsen, P., & Bitter, W. (2024). Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment. FEMS Microbiology Reviews. https://doi.org/10.1093/femsre/fuae011
Vancouver
Habjan E, Schouten GK, Speer A, van Ulsen P, Bitter W. Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment. FEMS Microbiology Reviews. 2024. doi:10.1093/femsre/fuae011
BibTeX
@article{Habjan2024,
author = {Habjan, Eva and Schouten, Gina K and Speer, Alexander and van Ulsen, Peter and Bitter, Wilbert},
title = {Diving into drug-screening: zebrafish embryos as an in vivo platform for antimicrobial drug discovery and assessment},
journal = {FEMS Microbiology Reviews},
year = {2024},
doi = {10.1093/femsre/fuae011}
}
EUVIMED